The next subsection therefore focuses on thymoma, a rare but immunologically distinctive malignancy in which early exploratory data suggest that EGFR-directed agents, recombinant monoclonal antibodies, and novel compounds such as Sitongzhi may open new avenues for patients who have historically lacked effective targeted options. The gene discussed is EGFR; the disease is thymoma.